Malecare Prostate Cancer Support Group

Clinical Trials

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By |2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment
Read More

On The Horizon – Some More Information & An Update On MDV3100

Many of us are aware of the newly approved drug Zytiga (abiraterone). It had demonstrated a survival advantage for men who are castrate resistant and failed chemotherapy. Zytiga was approved by the FDA in April and many of us with advanced prostate cancer have been taking advantage of the drug. You can learn more about [...]

By |2017-10-19T10:51:59-04:00October 16th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|2 Comments
Read More

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

By |2011-10-04T15:33:19-04:00October 4th, 2011|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Cabazitaxel, Chemo Therapy Failure, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, On The Horizon, Uncategorized, Zometa|1 Comment
Read More

A Goal Date for the Possible FDA Approval of Xgeva® (Denosumab) for men with Advanced Prostate Cancer

Amgen (NASDAQ: AMGN) today published a press release that said the U.S. Food and Drug Administration (FDA) will target an action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) (approval) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer with the goal of reducing the risk [...]

By |2011-08-23T09:47:50-04:00August 23rd, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, denosumab - Xgeva, FDA, Uncategorized, Understanding APC|1 Comment
Read More
Go to Top